Literature DB >> 3259466

Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates.

N Endo1, Y Takeda, N Umemoto, K Kishida, K Watanabe, M Saito, Y Kato, T Hara.   

Abstract

The binding of methotrexate (MTX) to IgG in conjugates was examined by studies on a direct MTX conjugate with a monoclonal antibody (aMM46) to mouse mammary tumor MM46 cells and corresponding irrelevant antibody and normal gamma-globulin conjugates, all prepared by the active ester method with MTX N-succinimidyl ester (MTX-OSu). The binding was examined in terms of effects on the potency and selectivity of the cytotoxic activity of the aMM46 conjugate. The results obtained supported the following conclusions: (a) MTX-OSu reacts not only with the amino group of IgG to give an amide bond, but also with another group(s) to give a less stable bond(s) such as an ester bond; (b) in contrast to the amide bond-linked MTX, which is taken up by the cells by endocytic internalization, a substantial portion of the MTX linked by an ester or other less stable bond(s) is released from the conjugates extracellularly and enters the cells by the MTX active transport system, as revealed by the inhibitory effect of thiamine pyrophosphate on the cytotoxicity; (c) this MTX linked by a less stable bond(s) that causes nonspecific cytotoxicity can be removed by treatment with hydroxylamine; (d) the overall cytotoxicity of aMM46-MTX decreased on removal of this less stably linked MTX, suggesting that the lysosomal degradation of the conjugate carrying amide bond-linked MTX to liberate MTX derivatives of low molecular weight is insufficient; (e) the liberation of low-molecular-weight substances in the lysosomes is probably more important for efficient entry of active substances into the cytosol, than for inhibition of the activity of dihydrofolate reductase, because after hydroxylamine treatment, the amide bond-linked MTX showed greater decrease in drug cytotoxicity than in inhibitory activity against dihydrofolate reductase; (f) in combination with hydroxylamine treatment, insertion between MTX and IgG of a linkage capable of ready cleavage in lysosomes deserves exploitation as a method for making potent conjugates with less nonspecific activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259466

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.

Authors:  P M Friden; L R Walus; G F Musso; M A Taylor; B Malfroy; R M Starzyk
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  Antibody-drug conjugates: Intellectual property considerations.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2015-08-20       Impact factor: 5.857

Review 3.  Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors:  V S Byers; R W Baldwin
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

Review 4.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

5.  Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody.

Authors:  N Umemoto; Y Kato; T Hara
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Selective killing of carcinoembryonic-antigen (CEA)-producing cells in vitro by the immunoconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208.

Authors:  T Iwahashi; Y Tone; J Usui; H Watanabe; I Sugawara; S Mori; H Okazaki
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues.

Authors:  B Ballou; R Jaffe; S Persiani; W C Shen; J J Langone; H Sands; J M Reilandu; J Curley; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.